Infertility is an important issue for patients with premature ovarian failure (POF). Although oocyte donation offers an alternative method to achieve a pregnancy, many patients seek to reproduce with their own gametes. We performed a literature search to evaluate the possibility of pregnancy following diagnosis, and the additional value of treatment strategies. We found 52 case reports, eight observational studies, nine uncontrolled studies and seven controlled trials. Due to a strong variability in study design, patient selection and mode of intervention, it was not possible to combine the data of the seven studies to perform a meta-analysis. None of the studies showed a statistically significant difference between both (or more) study groups. Due to a lack of incorporation of a placebo group, preference of any treatment over no treatment could not be established. Importantly, the collected data of observational, uncontrolled and controlled studies indicate that POF patients still have a 5-10% chance to conceive following diagnosis. Approximately 80% of the reported pregnancies resulted in the birth of a healthy child. There is no evidence that any treatment can enhance this pregnancy rate.
Introduction
Premature ovarian failure (POF) is characterized by a hypergonadotrophic hypo-oestrogenic oligo-or amenorrhoea. The cessation of ovarian function after puberty and before the age of 40 years (Coulam, 1982) strongly interferes with fertility and family planning. Although oocyte donation can fulfil the desire to create a family, little progress has been made towards improvement of reproduction with the patients' own gametes.
The diagnosis of POF affects around 10% of patients seeking evaluation of secondary amenorrhoea (Moraes Ruhsen and Jones, 1967) . Table I shows the diverse aetiology of POF (Rebar, 1982; Anasti, 1998) . However, in the majority of POF patients a cause cannot be identified, and they are diagnosed to have idiopathic POF. This group probably is still a heterogeneous one, consisting of patients with early follicular depletion and patients with the resistant ovary syndrome, in whom follicles are still present in the ovaries. Since differentiation between these forms would be essential to evaluate the benefit of therapeutic interventions, several authors performed biopsies or wedge resections either by laparoscopy or by laparotomy (Kinch et al., 1965; Emperaire et al., 1970; Zarate et al., 1970; Sharf et al., 1972; Starup and Sele, 1973; Falk, 1977; Duignan, 1978; Board et al., 1979; Rebar et al., 1982; Russell et al., 1982; Menon et al., 1984; Miyaka et al., 1987; Rebar and Conolly, 1990; Muechler et al., 1991) . They either found a few (in 30%) or numerous follicles (in 10%) in about 40% of all patients. However, several authors reported pregnancies occurring in patients with negative biopsies (Sutton, 1974; Polansky and Papp, 1976; Shangold et al., 1977) . So to date, biopsies are not helpful in predicting the potential of a patient to become pregnant.
Subsequently, it was reported that in 41-60% of patients with POF, follicle-like structures may be visualized in the ovaries with pelvic ultrasonography (Mehta et al., 1992; Nelson et al, 1994; Conway et al., 1996) . It was concluded (Nelson et al., 1994) that these follicles did not function normally, as there was a poor correlation between serum oestradiol concentration and follicular diameter. Six patients subsequently underwent biopsy of the antral follicles, and all biopsies showed luteinized follicles. Hence, it was postulated that premature luteinization may be the major pathophysiological mechanism in idiopathic POF. However, premature luteinization may be induced by diminished negative feedback on luteinizing hormone (LH) as a consequence of poor follicle performance, either in number or quality. As such, luteinization would not be the central pathophysiological mechanism, but rather a secondary phenomenon. Furthermore, as primordial follicles are too small to be detected with ultrasonography, patients with the resistant ovary syndrome cannot be identified with ultrasonography. Ovarian ultrasonography has not proven to be useful in predicting the potential for pregnancy.
As autoimmunity may play a role in POF, detection of autoantibodies has also been used as a screening tool. The assumption that POF might be an autoimmune disease is based on four observations. Firstly, POF is associated in some patients with other endocrinopathies with a known autoimmune cause, e.g. Addison's disease, autoimmune thyroiditis and myasthenia gravis (Edmonds et al., 1973; Irvine and Barnes, 1976; Coulam et al., 1981) . Secondly, there is a high prevalence of autoantibodies in POF patients (Mignot et al., 1989b; Rabinowe et al., 1989; Luborsky et al., 1990; van Weissenbruch et al., 1991) . Thirdly, changes in lymphocyte subsets have been found (Mignot et al., 1989a; Nelson et al., 1991; Hoek et al., 1995) . Finally, some authors have demonstrated lymphocyte and plasma cell infiltration around developing follicles in ovarian biopsies (Gloor and Hulimann, 1984; Sedmak et al., 1987) . However, we do not know whether these phenomena are causative or merely epiphenomena. Moreover, autoantibodies have no predictive value with respect to the possibility to conceive. Nonetheless, the presence of autoantibodies can be helpful in counselling patients, as autoantibodies against thyroid and adrenal cortex can precede the autoimmune disease by several years.
Genetic screening can reveal cytogenetic abnormalities, usually of the X-chromosome. Although this will not predict pregnancy potential in the index patient, it can be of great importance with respect to the future fertility of female relatives, particularly daughters of the index patient (Davison et al., 1998) .
To date, there are no tools available to categorize adequately the majority of POF patients according to aetiological factors, the presence of oocytes, or the potential to achieve a pregnancy. Consequently, therapeutic interventions have been directed towards a heterogeneous group of POF patients, usually but not always of idiopathic origin. Numerous case reports have shown that pregnancy can occur in POF patients (Table II) . It is doubtful, however, whether alleged therapeutic interventions played a role, as many pregnancies have been reported to occur spontaneously (Table II) . Thus, we searched the literature for evidence to support a real effect of any therapy, with respect to resumption of ovulation, and improvement of pregnancy rates in POF patients. Morrison et al., 1975; 3 Kaufman et al., 1986; 4 Waggoner et al., 1990; 5 Anasti, 1998; 6 Neuwinger et al., 1996; 7 Singh and Carr 1966; 8 Therman et al., 1990; 9 Sala et al., 1997; 10 Aittomaki et al, 1996;  11 Conway et al., 1998; 12 Partington et al., 1996; 13 Gloor and Hulimann, 1984; 14 Sedmak et al., 1987; 15 van Weissenbruch et al., 1991 . Jeppsson et al., 1980; 4 Hammerstein and Rommler, 1980; 5 Friedman et al.,1983; 6 Alper et al., 1986; 7 Kocijancic and Meden-Vrtovec, 1987; 8 Menashe et al., 1996; 9 Gucer et al., 1997; 10 Nakai et al., 1984; 11 Johnson and Peterson,1979; 12 Polansky and Papp, 1976; 13 Shapiro and Rubin, 1977; 14 Shangold et al., 1977; 15 Rosenwaks et al., 1978; 16 Starup et al., 1978; 17 Szlachter et al., 1979; 18 Brosens et al., 1979; 19 Voigt, 1984; 20 Oshawa et al., 1985; 21 Alper et al., 1986; 22 Petsos et al., 1986; 23 Le Pors et al., 1987; 24 Tinga and Lapphon, 1988; 25 Varma and Patel, 1988; 26 Tang and Sawers, 1989; 27 Galache Vega et al., 1989; 28 Lopez et al., 1989; 29 Jacobson et al., 1991; 30 Boulieu and Bully, 1993; 31 Helie et al., 1996; 32 Chen and Chang, 1997; 33 Check et al., 1989; 34 Amos, 1985; 35 Davis and Ravnikar, 1988; 36 Ishizuka et al., 1992; 37 Hellebaut et al., 1998; 38 Letterie and Miyazawa, 1989; 39 Ishizuka et al., 1997; 40 Busacca et al., 1996; 41 Meldrum et al., 1980; 42 Coulam et al., 1981; 43 Bateman et al., 1983; 44 Finer et al., 1985; 45 Rabinowe et al., 1986; 46 Cowchock et al., 1988; 47 Taylor et al., 1989; 48 Okuda et al., 1989; 49 Check, 1990 .
Reported pregnancies and livebirths in POF patients
An electronic search was performed on Medline over the period from January 1966 to February 1999. The search terms were: premature menopause, premature ovarian failure, premature gonadal failure, hypergonadotrophic ovarian failure, hypergonadotrophic amenorrhoea, and hypergonadotrophic hypogonadism, with controlled, randomized, therapy, treatment, oestrogens, gonadotrophin-releasing hormone (GnRH) analogues, LH-releasing hormone analogues, corticosteroids, ovulation and pregnancy. In addition, references of review articles were hand-searched. We found 52 case reports describing pregnancy or return of ovulation in patients with POF (Table II) . Eight observational studies mentioned the number of patients that had become pregnant in a group of POF patients (Table III) . Nine uncontrolled studies reported the number of patients that became pregnant in association with a specific intervention (Table IV) . Only seven trials appeared to be controlled.
The data of the uncontrolled, controlled and observational studies were analysed to obtain an estimate of the chance of pregnancy following diagnosis. The data of all reports were analysed to determine the chance of a livebirth, when pregnancy was achieved. Only the data of the controlled trials were used to estimate the additive effect of treatment.
In the observational studies, 4.8% of all women became pregnant, in the uncontrolled studies 18%, and in the controlled studies 1.5%. Overall, 6.3% of all women conceived after diagnosis. About 80% of the authors gave information on pregnancy results. In total, 112 pregnancies were available for analysis. Three pregnancies were terminated on request, 19 resulted in a miscarriage, one in a stillbirth at term, one in a tubal pregnancy, and five were still ongoing. Thus, 104 pregnancies resulted in the birth of 86 healthy children (three twin pregnancies). We did not find any reports on congenital malformations or chromosomal aberrations such as trisomy 21.
Effect of treatment in controlled studies
These seven controlled trials were analysed for methodology, inclusion and exclusion criteria, patient characteristics, type of intervention, and results. GnRHa = gonadotrophin-releasing hormone agonist; HMG = human menopausal gonadotrophin; OC = oral contraceptives.
The methodology of these trials is summarized in Table V . Six studies were randomized, and five of them described the method of randomization. One study (Surrey and Cedars, 1989) had no clear design. Patients were assigned to each treatment group by the investigators, and some participated in two groups. From the four studies with a cross-over design, only two (Nelson et al., 1992; Anasti et al., 1994 ) incorporated a wash-out period between the two treatment periods.
Inclusion and exclusion criteria of the controlled trials
A summary of the inclusion and exclusion criteria is given in Table VI . All studies shared the inclusion criterion of a serum follicle-stimulating hormone (FSH) concentration >40 mIU/ml, determined on at least two occasions. However, only two studies (Surrey and Cedars, 1989; Rosen et al., 1992) included patients with an amenorrhoea of >12 months duration. Four of the other studies incorporated women with an amenorrhoea of >4 months duration. In one study (Taylor et al., 1996) , a large proportion (27%) of the women had an amenorrhoea of only 2 months duration.
Four studies included primary as well as secondary amenorrhoea, and the other three only secondary amenorrhoea. Only in one study (Taylor et al., 1996) were several patients enrolled with an abnormal karyotype. Exposure to radiation, chemotherapy or extensive surgery (iatrogenic POF) was not excluded in this study. In summary, we conclude that the inclusion and exclusion criteria varied widely. 
Patient characteristics in the controlled trials
The characteristics of the patients included in the studies are presented in Table VII . The mean age ranged from 31 to 34 years between the studies. The median age ranged from 30 to 35 years. The interpretation of the duration of amenorrhoea is rather difficult. In two studies (Nelson et al., 1992; Anasti et al., 1994) , this was given as the time between diagnosis and study-entry, which would be an unreliable estimate in cases where a long period had elapsed from the start of amenorrhoea until diagnosis. Nevertheless, we accepted this as an estimate for the duration of amenorrhoea. The estimate from one study (Surrey and Cedars, 1989) was calculated by us from their data.
Other authors (van Kasteren et al., , 1999 ) gave duration of amenorrhoea as such, meaning the time elapsed since the last menstrual period; therefore, in their studies oligomenorrhoeic patients were listed as having an amenorrhoea of 0.3 years, even if they had been oligomenorrhoeic for many years. In contrast, in another study (Taylor et al., 1996) the mean duration of irregular menses (46.6 months) and the duration of elevated FSH concentration (14.9 months) were clearly stated. Obviously, a considerable proportion of the study subjects were only just entering the climacteric, and were not truly postmenopausal. For the present study, we took the duration of elevated FSH concentration as the estimate for duration of amenorrhoea. In one study (Surrey and Cedars, 1989) , only antibodies against thyroid and adrenal tissue were tested for, while in another report (Rosen et al., 1992) only patients without antibodies against thyroid tissue were included. All other authors tested for a range of organ-specific and non-specific autoantibodies. The percentage of patients that tested positive did not vary widely. With regard to the role of autoimmune phenomena, the patients in these studies seemed to be comparable between studies.
In summary, patient characteristics varied with regard to age at study entry, and duration of amenorrhoea.
Description of the intervention protocol of the controlled trials
In one study (Surrey and Cedars, 1989) , three protocols were compared: cyclic conjugated oestrogens/medroxy progesterone acetate (MPA), versus cyclic ethinyloestradiol/MPA, versus the GnRH agonist (GnRH-a) histerelin. In all three protocols the dose was increased until adequate suppression of FSH concentrations (<20 mIU/ml) was reached. As serum oestradiol concentration was used to monitor follicular activity, cyclic conjugated oestrogens were discontinued at the start of ovulation induction with human menopausal gonadotrophin (HMG; Pergonal  ). Ethinyloestradiol was continued at the same dose, and the GnRH-a at a lower dose. Gonadotrophin therapy was commenced at 150-300 IU daily, increasing to a maximum of 450 IU. The authors evaluated the effect of gonadotrophin therapy after restoration of a normogonadotrophic status.
In another study (Nelson et al., 1992) , a fixed suppression protocol was used in both treatment groups. One group received the GnRH-a deslorelin with cyclic oestradiol/MPA for 4 months, and the other group placebo received cyclic oestradiol/MPA. Ovarian function was monitored by weekly oestradiol measurements during a period of 8 weeks after discontinuing all medication. The authors were interested in a spontaneous restoration of follicular function as a rebound effect after pituitary suppression.
In addition, the difference between spontaneous resumption of ovulation and ovulation induction in the rebound phase after GnRH-a therapy was evaluated (Rosen et al., 1992) . Both patients groups received increasing doses of leuprolide acetate until serum FSH was suppressed to <25 mIU/ml. One group was then started on gonadotrophins (Pergonal  ), 150 IU daily, increasing to 300 IU after 5 days if necessary. Patient monitoring comprised weekly serum oestradiol measurements.
The spontaneous resumption of ovulation after pituitary suppression was investigated with a fixed protocol . Patients received either combined oestradiol/MPA or 800 mg danazol for 4 months. Monitoring consisted of weekly oestradiol measurements during a period of 8 weeks after stopping medication. The aim of the study was to examine differences between pure endocrine suppression (oestradiol/MPA) and combined endocrine and immune suppression (danazol) with regard to restoration of ovarian function.
In a later study , the effect of pituitary suppression with a GnRH-a (buserelin) on the ovarian response to gonadotrophins (Metrodin  ) was evaluated. The GnRH-a or placebo was continued at the same fixed dose during gonadotrophin therapy, the dose of gonadotrophins being increased weekly from 150 IU with 150 IU to 450 IU in 3 weeks. The authors evaluated the effect of creating a normogonadotrophic state before and during ovulation induction with gonadotrophins.
Subsequently, a study was performed (Taylor et al., 1996) to address the widely held belief that oestrogen replacement therapy would enhance resumption of ovulation, and thereby the chance of pregnancy. Patients received either 2 mg oestradiol or no therapy at all for 6 weeks. Monitoring consisted of weekly serum oestradiol measurements and pelvic ultrasonography.
The effect of immune suppression with corticosteroids on the ovarian response to gonadotrophin therapy was also studied (van Kasteren et al., 1999) . Patients received either 9 mg dexamethasone daily, or placebo daily, for 1 week. In the second week the dose was tapered. Gonadotrophin therapy was started on day 5 of the immune suppression. Monitoring was performed with serum oestradiol measurements on alternate days, and pelvic ultrasonography when a rise occurred in serum oestradiol concentrations.
Results of the controlled studies
The results of the studies in terms of ovulation and pregnancy are summarized in Table VIII . None of the studies showed a statistically significant difference between both (or more) study groups. Therefore, the results of both groups are depicted in combined form, except for the number of ovulatory cycles.
The primary endpoint for all studies was ovulation, as determined by serum progesterone concentration. In one study (Surrey and Cedars, 1989) , the concentration of serum progesterone was not defined, while in others (Nelson et al., 1992; Rosen et al., 1992; Anasti et al., 1994) a serum progesterone concentration >3 ng/ml was regarded as proof of ovulation. In a later study (Taylor et al., 1996) , a concentration of 4 ng/ml was taken as evidence of ovulation; this group had chosen a lower concentration than usual in their research (6 ng/ml) because of the weekly observations. Ovulation was defined according to urinary pregnanediol excretion of >3 µmol/24 h by one group , but in a subsequent study, the criteria for ovulation were not described as there was a total lack of ovarian response (van Kasteren et al., 1999) .
The criteria for ovulation varied in such a way that luteinization of unruptured follicles could have been mistaken as proof of ovulation. Progesterone concentrations in two ovulatory cycles of 4.2 and 3.2 ng/ml were reported in one study (Rosen et al., 1992) , while in a later study eight ovulations were found after danazol, compared with four ovulations after combined hormone replacement therapy (HRT). However, in eight of these ovulatory cycles (five in the danazol group, one in the combined HRT group), progesterone concentrations ranged between 3 and 4 ng/ml-concentrations which would not have been accepted as proof of ovulation by many researchers (e.g. Taylor et al., 1996) .
In one study (Nelson et al., 1994) , one pregnancy resulting in a miscarriage was reported, while in another study (Taylor et al., 1996) two pregnancies were reported which occurred within the study period. Three other women conceived within 8 months after initiation of the study, but after the study was closed. After 8 months, no other pregnancies ensued (total follow-up 48 months). Data on the outcome of five pregnancies in the study by Taylor et al. (1996) were not available.
Conclusions
Due to a strong variability in study design, patient selection and mode of intervention, it is not possible to combine the data of the seven studies to perform a meta-analysis. However, some conclusions can be drawn from these studies. The data again stress the importance of randomization in trials evaluating therapeutic intervention, since ovulations occurred almost always in both study groups. It can be argued that the power of the studies often was only sufficient to detect large differences of around 30%. However, most of the studies did not show a trend, that might have become a significant difference if the number of patients included had been expanded.
It is striking that, apart from one study (Taylor et al., 1996) , a 'placebo-only group' was not incorporated in any of the studies. Consequently, we can only conclude that several types of intervention are equally ineffective. We do not know whether or not these interventions should be preferred to no therapy at all. We presume that this phenomenon may be partly related to the urge to offer more than monitoring alone. Most patients and physicians would regard no therapy or placebo treatment combined with monitoring of no additive value to the standard strategy of expectant management. However, continuous monitoring of ovarian function in experimental settings may enhance timed intercourse, and thereby improve the chance of pregnancy.
The study referred to above (Taylor et al., 1996) did, however, incorporate a 'no therapy' group, but due to the liberal inclusion criteria would have needed a larger patient population and a longer observation period to detect differences between the groups. In this study, 46% of all patients ovulated, and 14.4% became pregnant during, or at some time after, the study. Even if one were to consider these patients as having merely incipient ovarian failure, this seems to be a high percentage compared with the other data (Scott and Hofmann, 1995) , which referred to an overall pregnancy rate of 5% in patients with an abnormal clomiphene citrate challenge test and regular cycles in a follow-up of 45 months.
It was found (Taylor et al., 1996) that 10/10 patients with an amenorrhoea of <2 months duration ovulated (100%), while only seven of 27 patients (26%) with an amenorrhoea of >3 months duration did so. This difference was statistically significant (P < 0.001). A trend to fewer ovulations with longer duration of amenorrhoea could also be observed in the other six studies of this review.
In the observational studies, 4.9% of all women became pregnant, compared with 18% in the uncontrolled intervention studies and 1.5% in the controlled studies. The low pregnancy rate found in the controlled studies may result, at least partly, from the short duration of these trials. The statistically significant higher pregnancy rate in the uncontrolled studies compared with the observational studies could be attributed mainly to two studies Blumenfeld et al., 1993) , without which the difference was not significant (9% versus 4.9%). These studies each showed a long follow-up, indicating that monitoring may have had a beneficial effect on the chance to conceive. However, monitoring per se has not been a subject in controlled trials. Furthermore, these data probably suffer from a strong positive publication bias, as uncontrolled studies with negative results are not likely to be published.
Nevertheless, the combined data of the observational, uncontrolled and controlled studies tentatively indicate that POF patients have a 5-10% chance of conceiving at some time after diagnosis. The pregnancy loss in these studies was 20%, which is quite similar to that of the normal population. There is no evidence that any treatment can improve this pregnancy rate. The widely held belief, that oestrogens enhance pregnancy in POF patients, is not substantiated. However, oestrogens certainly do not seem to be harmful to the reproductive potential.
The controlled studies performed until now have dealt with most of the theoretically useful approaches. Four out of six studies have suppressed gonadotrophins in one way or another. Hence, if premature luteinization were to be the central mechanism, these studies should have shown better results. Two studies focused on immunomodulation, though without success. Nonetheless, corticosteroids may be useful in autoimmune oophoritis, characterized by the presence of autoantibodies against steroid-producing cells (Hoek et al., 1997) . However, this form of POF is rare, and it would be practically impossible to collect enough patients to perform a randomized trial.
Future studies in this area should use strict inclusion criteria. POF patients represent a heterogeneous group, though this heterogeneity may be reduced by excluding primary amenorrhoea, iatrogenic causes, genetic causes, and causes known to reduce or destroy oocytes, as in galactosaemia. It is probable that we can only start to select patients adequately when a reliable method has been found to determine the presence of oocytes in the ovary. Studies should incorporate a 'placebo-only' group and, as the data suggest that POF patients do not ovulate every month, the treatment period should last at least several months. The primary endpoint should be pregnancy rate rather than ovulation, because restoration of ovarian endocrine function may not automatically imply improvement of oocyte quality. Henceforth, these studies would require a large number of participating patients in order to have adequate power.
In practical terms, a study which fulfils all these prerequisites can be executed only in a multicentre setting. More importantly, we should attempt to explore the factors that determine the dynamics of the oocyte pool and the quality of the oocyte in terms of its capacity to produce a healthy child.
